JAK inhibitors are increasingly being used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis because of its proven efficacy in the treatment of various chronic diseases.
The high unmet need for the treatment of graft-versus-host disease (GVHD) has also encouraged market vendors to develop novel drugs for GVHD. The lack of approved therapies for the treatment of rare cancer indications will also boost the demand for JAK inhibitors.
In 2018, the global Janus Kinase (JAK) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Janus Kinase (JAK) Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Janus Kinase (JAK) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Astellas Pharma, Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.
...

Market segment by Type, the product can be split into
Ruxolitinib
Tofacitinib
Oclacitinib
Baricitinib
Peficitinib

Market segment by Application, split into
Autoimmune Disorders
Oncology

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Janus Kinase (JAK) Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the Janus Kinase (JAK) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Janus Kinase (JAK) Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.